Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

a3380ca6-6c65-4543-9bdf-957b26c1daaf

de4f9234-8689-5cc5-a2aa-9774c19d8019

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
age_years
66.4175222450376

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.150
  • P53_PATHWAY+0.000
  • ESTROGEN_RESPONSE_EARLY-0.010
  • HEME_METABOLISM-0.020
  • UV_RESPONSE_UP-0.030
  • DNA_REPAIR-0.040
  • XENOBIOTIC_METABOLISM-0.050
  • MITOTIC_SPINDLE-0.060
  • WNT_BETA_CATENIN_SIGNALING-0.060
  • BILE_ACID_METABOLISM-0.080

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
  • ANGIOGENESIS-0.560
  • MTORC1_SIGNALING-0.400
  • ANDROGEN_RESPONSE-0.380
  • E2F_TARGETS-0.370
  • G2M_CHECKPOINT-0.350
  • INFLAMMATORY_RESPONSE-0.350
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
  • UV_RESPONSE_DN-0.330
  • MYC_TARGETS_V1-0.310

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR23303775
bladder-landscape@3
0.899
2SRR650134
bladder-landscape@3
0.892
3R87
bladder-landscape@3
0.890
420050097.LumA
breast-umap@18
B0.888
5SRR1388504
brain-umap@2
GTEX0.880
6MNG1271
mng-umap@100
0.877
7MDT-AP-0394
medullo-epn-umap@date-based
MedMedulloblastoma0.875
8SRR1377984
brain-umap@2
GTEX0.868
9MDT-AP-1160
medullo-epn-umap@date-based
MedMedulloblastoma0.866
10ULC0589T_S77
lung-landscapes@6
cohortA10.866

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 1 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.150Remibrutinib— uncovered